TOXICITY TO VARIOUS AGENTS and Potassium

Treatments might be new drugs or new combinations of drugs, new surgical procedures or devices, or new ways to use existing treatments. The goal of clinical trials is to determine if a new test or treatment works and is safe. Clinical trials can also look at other aspects of care, such as improving the quality of life for people with chronic illnesses. People participate in clinical trials for a variety of reasons. Healthy volunteers say they participate to help others and to contribute to moving science forward. Participants with an illness or disease also participate to help others, but also to possibly receive the newest treatment and to have the additional care and attention from the clinical trial staff.

Rank

Status

Study

Recruiting

Bioavailability of Potassium From Potatoes and Potassium Gluconate

Conditions:	Potassium Bioavailability; Blood Pressure
Interventions:	Dietary Supplement: Placebo control; Dietary Supplement: Low dose Potassium gluconate; Dietary Supplement: Medium dose Potassium gluconate; Dietary Supplement: High dose Potassium gluconate; Dietary Supplement: Low dose potato; Dietary Supplement: Medium dose potato; Dietary Supplement: High dose potato; Dietary Supplement: High dose French fries; Dietary Supplement: Basal diet control
Outcome Measures:	Bioavailability of Potassium; Blood Pressure Response to Potassium

Not yet recruiting

Clinical Decision Support System for Quality Assurance in Potassium-Increasing Drug-Drug-Interactions

Condition:	Hyperkalemia
Intervention:	Behavioral: decision support in Potassium-inc. drug-drug-interactions
Outcome Measures:	Impact on serum Potassium monitoring during Potassium-increasing drug-drug-interactions; Frequency of hyperkalemia during Potassium-increasing drug-drug-interactions; Frequency of Potassium-increasing drug-drug-interactions ordered in the presence of hyperkalemia; Frequency of transfers to the ICU during Potassium-increasing drug-drug-interactions in function of the serum Potassium level; Frequency of death during Potassium-increasing drug-drug-interactions in the presence or absence of hyperkalemia; Change in frequency distribution of serum Potassium monitoring intervals; Response of physicians to the computer-based alerts and reminders

Recruiting

Comparison of Enteral Versus Intravenous Potassium Supplementation

Condition:	Acute Hypokalemia
Interventions:	Drug: Intravenous Potassium chloride; Drug: Oral Potassium chloride
Outcome Measures:	The efficacy EPR and IVPR for treatment of hypokalemia (measured as change in serum Potassium levels in milliequivalent/liter (mEq/L) after Potassium replacement; Comparison of adverse effects after EPR and IVPR.; Comparison of number of dose/s required to achieve resolution of hypokalemia; Efficacy of EPR and IVPR for various degrees of severity of hypokalemia for each episode of hypokalemia

Unknown ^†

Effect of Rapid Transfusion With Fluid Management System (FMS) on Plasma Potassium in Liver Transplantation Recipients

Condition:	Condition Requiring Rapid Transfusion During Liver Transplantation Surgery
Intervention:
Outcome Measures:	Potassium concentration in the Fluid Management System (FMS) reservoir; plasma Potassium of the patient

Not yet recruiting

Study to Assess the Efficacy and Safety of Oral Potassium Citrate on the Prevention of Nephrocalcinosis in Extreme Premature

Condition:	Nephrocalcinosis
Interventions:	Drug: Potassium Citrate; Drug: Placebo
Outcome Measures:	incidence of nephrocalcinosis in extremely preterm infants; Determine whether the administration of Potassium citrate in extreme premature decreases neonates the levels of calcium and calcium / creatinine ratio in urine in each of the branches of treatment at 38-40 weeks; To determine whether administration of Potassium citrate improves the levels of urinary phosphorus, Potassium, sodium, citrate, creatinine, oxalate, ratio citrate / calcium , and ph value; Determine whether the administration of Potassium citrate improves the plasma levels of sodium, Potassium, creatinine, calcium, and ph value.; To determine the incidence of adverse events and serious adverse events related to study treatment.

Unknown ^†

Effects of Potassium Salts on Blood Pressure and Target Organ Damage

Condition:	Hypertension
Intervention:	Behavioral: Potassium supplementation
Outcome Measures:	Blood pressure and markers of target organ damage and bone health at 4 weeks of Potassium supplementation.; Comparisons among different treatments in blood pressure and markers of target organ damage and bone health.

Recruiting

Value of Liquid Potassium Magnesium Citrate in Controlling Hypertension

Condition:	Hypertension
Interventions:	Drug: Potassium chloride powder; Drug: Potassium citrate powder; Drug: Potassium magnesium citrate powder; Drug: Placebo
Outcome Measures:	24-hour blood pressure; Office blood pressure; Serum C-terminal telopeptide (CTX); 24-hour urinary calcium; Carotid to femoral pulse wave velocity; Central aortic blood pressure

Recruiting

Potassium Infusion for Conversion of Atrial Fibrillation/-Flutter

Conditions:	Atrial Fibrillation; Atrial Flutter; Potassium; Cardioversion
Intervention:	Drug: Potassium chloride
Outcome Measures:	Cardioversion (time and percentage); Atrial fibrillation at 3 months follow up visit and during 72 hours ECG-monitoring period.

Recruiting

Combined Dietary Education of Low Sodium and High Potassium Consumption

Conditions:	Prehypertension; Hypertension
Interventions:	Behavioral: dietary education of low sodium and high Potassium consumption; Behavioral: dietary education of low sodium consumption only
Outcome Measures:	changes of 24-hour ambulatory systolic and diastolic blood pressure; changes of 24-hour urine sodium and Potassium excretion; changes of renin and aldosterone

Not yet recruiting

Investigating a New Way of Giving Medicine to Newborn and Preterm Babies

Conditions:	Hypophosphataemia; Osteopenia of Prematurity
Interventions:	Drug: Oral thin film therapy (Potassium acid phosphate oral thin films); Drug: Standard therapy (Potassium acid phosphate oral solution)
Outcome Measures:	Serum phosphate; Age-appropriateness

Unknown ^†

Glucose Insulin Potassium With Intensive Insulin Therapy and (GIK2) Versus GIK Alone

Condition:	Acute Coronary Syndrome
Interventions:	Drug: glucose insulin Potassium; Drug: GIK and intensive insulin therapy
Outcome Measures:	30 days mortality, reinfarction, urgent coronary revascularisation, and stroke.; Severe dysrhythmias, acute left ventricular failure with ejection fraction<45%, change of serum B-type natriuretic peptide (BNP), serum troponin, and platelet factor activator (PFA-100) within 24 hours after the start of protocol treatment.

Recruiting

Potassium Citrate Supplementation vs. Dietary Counseling

Condition:	Kidney Stone
Interventions:	Dietary Supplement: Potassium Citrate Supplementation; Other: Dietary Education
Outcome Measure:	Change in 24-hour urine parameters

Recruiting

Musculoskeletal Effects of Bicarbonate

Conditions:	Age-related Bone Loss; Age Related Muscle Loss; Falls; Fractures
Interventions:	Dietary Supplement: Potassium bicarbonate; Other: placebo
Outcome Measures:	The primary aim is to identify the dose of KHCO3 needed for maximal suppression of 24-hr urinary N-telopeptide/creatinine ratio; The secondary aim is to identify the dose of KHCO3 needed for maximal suppression of 24-hr urinary nitrogen/creatinine ratio

Recruiting

Perioperative Chemotherapy for Potentially Resectable Gastric Cancer

Condition:	Gastric Cancer
Interventions:	Drug: Tegafur, Gimeracil and Oteracil Potassium Capsules；Oxaliplatin; Drug: Oxaliplatin; Capecitabine
Outcome Measures:	Disease-free survival(DFS); Objective response rate (ORR); Disease control rate (DCR); Down staging rate; Overall survival (OS); Adverse events; R0-resection rate

Unknown ^†

Efficacy and Tolerance of Potassium Hydroxide (10% and 15%) in Molluscum Contagiosum

Condition:	Molluscum Contagiosum
Interventions:	Drug: Hydroxide Potassium; Drug: Placebo
Outcome Measure:	Efficacy (diseappearance of lesions)

Unknown ^†

The Effects of Potassium Citrate on Bone Metabolism

Conditions:	Bone Diseases, Metabolic; Osteoporosis, Postmenopausal
Intervention:	Drug: Potassium citrate
Outcome Measures:	Bone turnover markers; Bone Density by DEXA

Recruiting

Effectiveness of Two Water-Based Potassium Oxalate Desensitizers on Dental Hypersensitivity

Condition:	Dentin Sensitivity
Intervention:	Device: Potassium oxalate
Outcome Measure:	Dentin sensitivity

Recruiting

Efficacy and Safety of Shenyankangfu Tablets for Primary Glomerulonephritis

Conditions:	Glomerulonephritis; Proteinuria
Interventions:	Drug: Shenyankangfu tablets; Drug: Losartan Potassium 50mg; Drug: Shenyankangfu tablets and Losartan Potassium 50mg; Drug: Shenyankangfu tablets and Losartan Potassium 100mg; Drug: Losartan Potassium 100mg
Outcome Measures:	changes of 24 hours proteinuria after the treatment; changes of serum creatinine after treatment; changes of eGFR after the treatment; changes of Traditional Chinese Medicine syndrome scores after the treatment

Recruiting

Comparison Between Oxomemazine, Guaifenesin and Potassium Iodate Versus Guaifenesin Monotherapy in Acute Cough Treatment

Condition:	Cough
Interventions:	Drug: Syrup of oxomemazine, guaifenesin and Potassium iodate; Drug: Syrup of guaifenesin
Outcome Measures:	Reduction/improvement of cough symptoms; Tolerance

Unknown ^†

Relationship Between Potassium Level in Venous Blood Samples Drawn and Heel Sticks In Infants and Newborns

Condition:	Healthy Infants
Intervention:
Outcome Measure:	Potassium Measurements